Nanobiotix annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix EBITDA Growth & History (NANO)
Nanobiotix's calculated EBITDA was −€9.3M for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€9.3M | €57.4M | — |
| 2024 | 2024-12-31 | −€66.8M | −€41.5M | — |
| 2023 | 2023-12-31 | −€25.3M | €19.9M | — |
| 2022 | 2022-12-31 | −€45.2M | €5.8M | — |
| 2021 | 2021-12-31 | −€51.0M | −€16.3M | — |
| 2020 | 2020-12-31 | −€34.7M | €10.3M | — |
| 2019 | 2019-12-31 | −€45.0M | −€15.6M | — |
| 2018 | 2018-12-31 | −€29.4M | — | — |
Nanobiotix ebitda trends
Over the last five fiscal years, Nanobiotix's ebitda increased from −€34.7M to −€9.3M, a change of €25.4M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
